Physician profile
Christine M Abt
NPI 1073546016
$2,342.77
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $691 · 2022: $824 · 2023: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $549.60 | 2021-2023 | Vraylar |
| Janssen Pharmaceuticals, INC | $303.14 | 2021-2023 | Invega Sustenna, Invega Trinza |
| Corium, LLC | $280.84 | 2022-2023 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $220.20 | 2021-2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $129.24 | 2021-2023 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.40 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $84.82 | 2021-2022 | |
| Lundbeck LLC | $78.15 | 2021-2023 | Rexulti |
| Harmony Biosciences LLC | $74.50 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $66.72 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $60.34 | 2021-2023 | Ingrezza |
| Jazz Pharmaceuticals INC. | $59.83 | 2021 | |
| Alkermes, INC. | $50.71 | 2022-2023 | Aristada, Lybalvi |
| Eisai INC. | $47.40 | 2021-2022 | |
| Bausch Health US, LLC | $40.15 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $40.02 | 2023 | Auvelity, Sunosi |
| Adlon Therapeutics L.P. | $34.39 | 2021 | |
| Supernus Pharmaceuticals, INC. | $32.20 | 2022-2023 | Qelbree |
| Avanir Pharmaceuticals, INC. | $20.73 | 2022 | |
| Tris Pharma INC | $20.15 | 2023 | Dyanavel Xr |
| Almatica Pharma LLC | $19.88 | 2021 | |
| Idorsia Pharmaceuticals US INC | $14.64 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $12.72 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Abt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.